07 Apr 2025
Labcorp has introduced a new blood test designed to assess the risk of Alzheimer’s disease by detecting elevated levels of amyloid beta proteins in the brain—a key biomarker associated with the condition. The test, which uses mass spectrometry and can be ordered by physicians, offers a less invasive and more accessible option than traditional PET imaging or spinal taps. Experts believe it could help accelerate diagnoses and expand early intervention opportunities for patients experiencing memory loss or cognitive decline. Read the full article on MedTech Dive to learn more about this breakthrough in Alzheimer’s screening.